Epidemiology Study in Postmenopausal Women With Estrogen Receptor Positive Breast Cancer
This observational study in estrogen receptor positive early breast cancer patients is aimed to evaluate the patients' compliance to aromatase inhibitor (AI) therapy and to collect country-specific data in estrogen receptor positive early breast cancer patients including data on demography, disease characteristics and disease management.
Hormon Receptor Positive Breast Cancer
Evaluate compliance rate, as assessed by investigator, after 12 months from baseline., 12 months
Evaluate compliance rate, assessed by investigator, after 6 months of follow up, 12 months|Evaluate the extent of patient educational activities as assessed by patient (using patient questionnaire) after 6 and 12 months, 12 months|Evaluate patient compliance as assessed by the patient (using patient questionnaire) after 6 and 12 months, 12 months|Collect epidemiology data; Demographic data: age, height, weight, lifestyle, menarche, childbirth, lactation, menopausal status, 12 months|Primary disease (breast cancer) characteristics: receptor status, disease stage, 12 months|Disease management data: treatment/treatment changes, 12 months
This observational study in estrogen receptor positive early breast cancer patients is aimed to evaluate the patients' compliance to aromatase inhibitor (AI) therapy and to collect country-specific data in estrogen receptor positive early breast cancer patients including data on demography, disease characteristics and disease management.